Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug/biomarker concentrations.
暂无分享,去创建一个
Roland F Staack | Gregor Jordan | Julia Heinrich | Uwe Dahl | Julia Heinrich | Gregor Jordan | R. Staack | Uwe Dahl
[1] V. Wroblewski,et al. Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments , 2013, mAbs.
[2] Bing Kuang,et al. Therapeutic monoclonal antibody concentration monitoring: free or total? , 2010, Bioanalysis.
[3] Boris Gorovits,et al. Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation , 2013, The AAPS Journal.
[4] E. D. De Palo,et al. Effects of two different types of exercise on GH/IGF axis in athletes. Is the free/total IGF-I ratio a new investigative approach? , 2008, Clinica chimica acta; international journal of clinical chemistry.
[5] Yong Huang,et al. Matrix effect and recovery terminology issues in regulated drug bioanalysis. , 2012, Bioanalysis.
[6] V. Quarmby,et al. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development. , 2011, Bioanalysis.
[7] H. Kim,et al. Copyright � The Korean Academy of Medical Sciences The Levels of Circulating Vascular Endothelial Growth Factor and , 2006 .
[8] Tong-Yuan Yang,et al. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. , 2013, Bioanalysis.
[9] Heather Myler,et al. Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.
[10] Denise M O'Hara,et al. Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.
[11] Valerie Theobald,et al. Life cycle management of critical ligand-binding reagents. , 2013, Bioanalysis.
[12] J. Sailstad,et al. Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.
[13] Roger Hayes,et al. Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilars. , 2012, Bioanalysis.
[14] A. Ahene. Application and interpretation of free and total drug measurements in the development of biologics. , 2011, Bioanalysis.
[15] T. Prueksaritanont,et al. Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of ‘Free’ and ‘Total’ Drug and Target , 2011, Pharmaceutical Research.
[16] A. Lucia,et al. Effects of an endurance cycling competition on resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and IGFBP-3 , 2001, British journal of sports medicine.
[17] A. Drake,et al. Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. , 2012, Analytical biochemistry.
[18] Viswanath Devanarayan,et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.
[19] Roland F Staack,et al. Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification. , 2012, Bioanalysis.
[20] H. Yoshida,et al. Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples , 2004, Clinical chemistry and laboratory medicine.
[21] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.
[22] R. Faggioni,et al. PK-PD modeling of protein drugs: implications in assay development. , 2011, Bioanalysis.
[23] Apollon Papadimitriou,et al. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. , 2011, Bioanalysis.
[24] Viswanath Devanarayan,et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.
[25] Rafael Ponce,et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.
[26] Jean W Lee,et al. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. , 2009, Bioanalysis.